 |
News
-
IGBA’s Annual Global Biosimilars Week Focuses on Oncology Care (November 2023)
Geneva, November 13, 2023 – In the week ahead, IGBA will renew its commitment to raise awareness of the powerful and lifechanging impact of biosimilar medicines which contribute to delivering better health outcomes and biologics access equity for more patients. The
… Read More -
IGBA and WHO collaborate on expanding access to quality-assured generic and biosimilar medicines (October 2023)
On October 27, 2023, the International Generics and Biosimilars Medicines Association (IGBA), including members of IGBA’s CEO Advisory Committee, met with World Health Organization (WHO) Director-General Dr. Tedros Adhanom Ghebreyesus in Geneva. During the full-day meeting, IGBA company and member
… Read More -
IGBA’s CEO Advisory Committee Meets with WIPO Director General Daren Tang (October 2023)
The International Generic and Biosimilar Medicines Association’s (IGBA) CEO Advisory Committee held an exchange with Mr. Daren Tang, Director General of the World Intellectual Property Organization (WIPO). This was the first opportunity for Mr. Tang to engage in a direct
… Read More -
ANAFAM, the National Association of Medicines Manufacturers of Mexico, joins IGBA (September 2023)
IGBA, the International Generic and Biosimilar medicines Association, representing global manufacturers of generic and biosimilar medicines, announced today that ANAFAM has been accepted and welcomed as a new IGBA Associate Member.
Read More -
Global regulators and biopharmaceutical and vaccine industry to share experiences with managing pharmaceutical quality systems (July 2023)
On 20 July 2023, the International Coalition of Medicines Regulatory Authorities (ICMRA) is hosting a virtual workshop on the development of a global Pharmaceutical Quality Knowledge Management System (PQ KMS), which aims to facilitate the exchange of knowledge related to
… Read More -
IGBA Welcomes ICH New Topic for Harmonisation: “Bioequivalence for Modified-Release Products” (June 2023)
The International Generic and Biosimilar Medicines Association ( IGBA ) commends the General Assembly of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use ( ICH ) for its adoption of a new topic focused on the harmonisation of " Bioequivalence
… Read More -
IGBA CEO Advisory Committee Vienna Statement - Four Keys to More Predictable Supply Chains (June 2023)
Vienna, June 14, 2023 - The COVID-19 pandemic demonstrated the critical importance of resilient global supply chains. As the CEO Advisory Committee of the International Generic and Biosimilar Medicines Association (IGBA), we underscore the essential role of the off-patent pharmaceutical sector
… Read More -
IGBA detailed comments and proposals on the Pandemic Accord (Zero Draft - May 2023)
IGBA is pleased to share key comments and proposals on selected provisions of the Zero Draft of the Pandemic Accord
Read More -
IGBA Perspectives on Pandemic Accord (Zero Draft – April 2023)
The criticality of supply chain resilience has become increasingly apparent in recent years, including for essential medicines and health products. The COVID-19 pandemic and geopolitical tensions have highlighted certain vulnerabilities of global supply chains, particularly in the areas of raw
… Read More -
IGBA nominated David Gaugh, AAM's Interim CEO, as the new IGBA Chair for 2023 (April 2023)
IGBA informs that Jonathan Kimball is no longer part of the staff of the Association for Accessible Medicines (AAM), our U.S. IGBA Member, and hence, is no longer in the position as IGBA Chair. Subsequently, David Gaugh , AAM's Interim CEO,
… Read More -
IGBA’s 25th Annual Conference highlights the true value of the off-patent medicines industry for patients and health systems around the world (February 2023)
IGBA, the International Generic and Biosimilar medicines Association, representing global manufacturers of generic and biosimilar medicines, announced today that experts and leaders from the local and global generic and biosimilar medicines industries, Government and regulatory agencies, academia and other stakeholders
… Read More -
Jonathan Kimball takes over the position of IGBA Chair (January 2023)
The International Generic and Biosimilar Medicines Association (IGBA), representing global manufacturers of generic and biosimilar medicines, announced today that Jonathan Kimball, Vice President of Trade and International Affairs of the Association for Accessible Medicines (AAM), Vice-Chair IGBA and Vice Chair
… Read More
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
